Question: why is icpt stock down?
Answer: Intercept Slumps as the FDA Issues CRL to NASH Candidate Intercept (ICPT) down on receipt of CRL for its NDA seeking approval of OCA for the treatment of fibrosis due to nonalcoholic steatohepatitis (NASH).